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Toxicant Exposure in Cigarette Reducers versus Light Smokers
Dorothy K. Hatsukami, Chap T. Le, Ying Zhang, Anne M. Joseph, Marc E. Mooney,
Steven G. Carmella, and Stephen S. Hecht
University of Minnesota Transdisciplinary Tobacco Use Research Center and the Cancer Center, Minneapolis, Minnesota
Abstract
Background: The extent of exposure to tobacco toxicants in
smokers who have reduced their cigarette intake com-
pared with smokers who are light smokers is relatively
unknown. The goal of this study is to investigate the
occurrence of compensatory smoking in reducers com-
pared with light smokers by measuring toxicant expo-
sure.
Methods: Participants in two smoking reduction interven-
tion studies (N = 64) were selected for comparison with a
group of light smokers (N = 62) who smoked the same
number of cigarettes as the reducers. A compensatory
smoking score was defined (biomarker level for reducer/
biomarker level for light smoker) and calculated for urinary
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and
its glucuronides (total NNAL), metabolites of the tobacco-
specific lung carcinogen 4-(methylnitrosamino)-I-(3-pyr-
idyl)-1-butanone, to measure the degree of smoking
compensation in reducers when compared with the light
smokers.
Results: Themean level of creatinine-adjusted total NNAL for
reducers was over twice that of light smokers even when they
smoked about the same number of cigarettes per day. The
difference of the mean total NNAL concentrations between
light smokers and reducerswas highly significant (P < 0.0001).
Wide variability in total NNAL concentrations was also
observed in reducers, with the extent of this variability
between light smokers and reducers being significantly
different (P = 0.0005). The level of individual reduction was
shown to be a consistent predictor of compensatory smoking
(r = 0.50; adjusted Ps = 0.002), with greater cigarette reduction
associated with more compensation.
Conclusions: Compensatory smoking limits the harm reduc-
tion value of decreased smoking of cigarettes. (Cancer
Epidemiol Biomarkers Prev 2006;15(12):2355–8)
Introduction
Compensatory smoking refers to changes in smoking behavior
to adjust for changes in nicotine levels of a tobacco product or
changes in amount smoked (1-4). To maintain nicotine levels,
smokers increase the extent to which each cigarette is smoked
through greater inhalation of mainstream smoke (3). In large
part, this compensatory smoking occurs because tobacco use
behavior is considered to be primarily driven by nicotine,
with users trying to maintain a specific level of nicotine in
their bodies (5). Other factors, such as the sensory aspects of
smoking or cigarette design, may also play a role in compen-
satory smoking (6).
Compensatory smoking that occurs during reduced ciga-
rette smoking may result in less reduction in exposure to
tobacco-related toxicants than is evident by the extent of
cigarette reduction. In a recent study of scheduled smoking
reduction using nicotine replacement therapy (7), we observed
that smokers who experienced an average of 73% reduction in
daily cigarette consumption only showed a 30% reduction in
carcinogen uptake as measured by 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol (NNAL) and its glucuronides (total
NNAL). Total NNAL is composed of metabolites of the
tobacco-specific lung carcinogen 4-(methylnitrosamino)-I-
(3-pyridyl)-1-butanone. In an epidemiologic study examining
the effect of cigarette reduction on lung cancer risk, smokers
who reduced their mean tobacco consumption by at least 50%,
from a mean of 22.2 g/d to 8.5 g/d, had an adjusted hazard
ratio (HR) of 0.73 compared with heavy smokers (8). Therefore,
a reduction of 62% in tobacco consumption amount was
associated with only a 27% reduction in lung cancer risk. Thus,
the risk reduction is markedly less with smoking reduction
and similar to the extent of reduction in total NNAL observed
in the study conducted by Hecht et al. (7). The purpose of the
current study was to further explore this area by examining the
extent of compensatory smoking in the context of smoking
reduction with nicotine replacement therapy compared with a
group of light smokers who smoked comparable cigarettes.
Compensatory smoking was assessed by levels of total NNAL.
Materials and Methods
Study Populations. The smoking and biomarker data from
four cohorts of smokers were merged to select our two
samples. Two of the cohorts, 1 and 2, were participants in
clinical trials. The other two cohorts, 3 and 4, were recruited
specifically for their low smoking rates.
Cohort 1 included participants from a clinical trial, the
Tobacco Reduction Intervention Program study, which
recruited cigarette smokers ages 18 to 70, who were interested
in reducing but not quitting cigarette use in the next 30 days.
This study involved reducing smoking by 25% of baseline the
first 2 weeks, 50% the subsequent 2 weeks, and 75% for the
final 2 weeks. Reduction was achieved through the use of
nicotine replacement products (i.e., 4 mg nicotine gum and 14
and 21 mg transdermal nicotine patch), which were made
available to subjects for up to 12 weeks. Subjects were asked to
sustain at least a 50% reduction for the next 12 weeks. They
were screened to ensure they met the following eligibility
criteria: (a) smoking 15 to 45 cigarettes per day (CPD) for the
past year, (b) apparent good health with no unstable medical
condition, (c) no contraindications to nicotine replacement use,
(d) good mental health, (e) not using other tobacco products,
and (f) not pregnant or nursing. The average number of CPD
was calculated from a daily diary. This study design and the
results and methods for analysis of creatinine-adjusted total
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NNAL are described in full detail in an earlier publication (7).
Levels of cotinine, a metabolite of nicotine, were also assessed
but excluded from analyses because of the confounding effects
from the nicotine replacement products. Only the smoking and
biomarker data collected at baseline and at 6-month follow-up
were analyzed for this study.
Cohort 2 included participants from a clinical trial, the
Reduction of Smoking in Cardiac Patients study. This study
included cigarette smokers ages 18 to 80 with at least one
diagnosis of heart disease who were interested in reducing
smoking but not quitting in the next 30 days. The study design
involved randomly assigning smokers with cardiovascular
disease to a smoking reduction intervention using nicotine
replacement treatment or usual care (e.g., advice and brief
assistance for smoking cessation). Eligibility criteria included
the following: (a) smoking z15 CPD; (b) having at least one of
the following diagnoses: coronary artery disease, arrhythmia,
congestive heart failure, peripheral vascular disease, or history
of cerebrovascular disease; (c) no unstable angina in the past
2 weeks; (d) no unstable mental health or substance use
diagnoses; and (e) no contraindications to nicotine replacement
therapy (including pregnancy or intention to become preg-
nant). The average number of CPD was calculated from recall
of the smoking level in the past week. This cohort was merged
with cohort 1, and only the smoking and biomarker data at
baseline and at 6-month follow-up were analyzed.
As the comparison group, low-level smokers were recruited
from the Minneapolis-Saint Paul metropolitan area (Adult
Cross-sectional Study, cohort 3) and the Minneapolis Veterans
Affairs Medical Center (Low Level Smoking Study, cohort 4).
Eligibility criteria for cohort 3 were the same as for cohort 1;
however, participants had to smoke <15 CPD at a stable level
for a minimum of 1 year. Eligibility criteria for cohort 4 were
the same as for cohort 2; however, participants also had to
smoke <15 CPD at a stable level for a minimum of 1 year.
These smokers were seen one to two times (corresponding to
baseline data collected for the clinical trials) to obtain a history
and biomarker specimens. For subjects who came in twice in
the baseline phase (cohorts 1 and 3), data values were
averaged.
The Institutional Review Board of the University of
Minnesota (Minneapolis, MN) approved the study protocols.
Written consent was obtained from all volunteers at the
orientation visit, where detailed information was given about
the study protocols.
Study Samples. The reducers consisted of 64 participants in
clinical trials: cohorts 1 (n = 48) and 2 (n = 16). Reducers were
selected from cohorts 1 and 2 using on these two criteria: (a)
they reduced their CPD at least 40% from enrollment to
6-month follow-up and (b) at 6 months, they smoked no more
than 10 CPD (the maximum number of cigarettes observed
from sample 1). The light smokers sample consisted of 62
smokers from cohorts 3 (n = 55) and 4 (n = 7). The aim here
was to create two study samples with similar smoking levels.
Measure of Smoking Compensation. At any point in time,
the rate of tobacco biomarker exposure can be calculated as an
exposure rate: M/C . In this formula, a marker of smoking
exposure (e.g., total NNAL) is denoted as M and daily
cigarette consumption (cigarettes per day) as C . This rate
defines amount or quantity of a biomarker per cigarette
smoked (e.g., creatinine-adjusted total NNAL per cigarette).
Change in the exposure rate from one time to another or from
one subgroup to another can be used to index compensation.
Compensatory smoking reflects increased uptake of main-
stream smoke relative to the number of cigarettes smoked.
Compensatory smoking may be evaluated as a compensation
rate difference, M1/C1  M0/C0, where 0 refers to baseline
and 1 to a time period assessed during cigarette reduction.
Alternatively, compensatory smoking may be appraised as a
compensation rate ratio (CRR; refs. 9, 10)
CRR ¼ Ma=C1
M0=C0
Compensatory smoking has, in fact, been defined in several
ways and measured by several different statistics (1, 3, 4, 11),
but all these methods are primarily different functions of the
above exposure rate. The common weakness of these measures
of compensatory smoking is that exposure rate implicitly
assumes a linear and proportional relationship betweenM and
C . In reality, the relationship between M and C may be
depicted as a sigmoid curve. We adopted a modified version of
the CRR statistics to describe the level of compensatory
smoking, where we fixed a common value for C and defined
CRR as the ratio M1/M0. Therefore, CRR was calculated by
comparing the extent of biomarker exposure in smokers who
had reduced (M1) versus smokers who were persistent light
smokers (M0) rather than the extent of change in biomarkers
per cigarette within a smoker overtime.
Results
Comparison of Study Samples. Light smokers had an
average age of 47.7 years (range, 19-75), were 53% female, and
smoked a mean of 5.6 CPD (range, 1-10). Reducers had an
average age of 51.2 years (range, 20-73), were 39% female, and
smoked a mean of 26.0 CPD (range, 15-50). All subjects in
the second group reduced their smoking by at least 40%
and, on the average, smoked 5.0 CPD at 6 months after
enrollment (range, 1-10). The differences in age (P = 0.11) and
sex (P = 0.11) between the groups, although rather small and
only near significant, were adjusted in the comparison of mean
total NNAL.
Comparison of Total NNAL. The descriptive statistics for
mean (SD) total NNAL for both study samples are listed in
Table 1.
A box plot is shown in Fig. 1.
Table 1. Descriptive statistics for mean (SD) total NNAL in
light smokers and reducers
Sample n Total NNAL (pmol/mg creatinine)
Mean SD 95% CI
Light smokers 62 0.85 0.80 0.65-1.05































Figure 1. Variability in total NNAL (pmol/mg creatinine) in light
smokers and reducers.
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The major aim here was to compare the average total NNAL
level for light smokers versus the average total NNAL level for
reducers measured at 6 months when both groups have similar
levels of smoking.
The data showed that the two study samples corresponded
to very different levels of variation. The ratio of sample
SD, reducers divided by light smokers, was 1.25 / 0.80 = 1.56.
The difference was highly statistically significant (F = 2.46;
P = 0.0005). More importantly, the mean level of total NNAL
for reducers was much higher than that of light smokers. The
ratio of sample means in reducers divided by light smokers was
2.07 / 0.85 = 2.43. We did a statistical comparison of means with
the two-sample t test using the Satterthwaite method to account
for lack of homogeneity of variance. The difference was highly
statistically significant (t = 6.54; P < 0.0001).
Because subjects in the two study samples had somewhat
different age and sex composition, we adjusted our compar-
ison of mean total NNAL for possible confounding effects of
age and sex. Using individual total NNAL level as the
dependent variable, a multiple regression analysis was done
on three independent variables: sample membership, age, and
sex. The adjusted difference (in total NNAL adjusted for age
and sex) was also highly significant; instead of a difference
2.07  0.85 = 1.22 pmol/mg creatinine, the adjusted difference
(slope of the sample membership indicator) was 1.27 pmol/mg
creatinine (t = 6.57; P < 0.0001).
Investigation of Compensatory Smoking. For each subject
in the sample of reducers, the subgroup of light smokers
having the same CPD as the reducers at 6 months was
identified. The average total NNAL measured from each
reducer at 6 months (M1) was divided by average total NNAL
of his/her CPD-matched subgroup of light smokers (M0) to
obtain his/her individual CRR. The mean of CRRs for
subgroups of reducers with the same CPD was calculated
and is shown in Table 2; the average CRR ranged from 94% to
841%. The vast majority was >100% and the fewer the CPD, the
higher the compensation index.
Using individual CRR index level as the dependent variable,
a multiple regression analysis was done on three dependent
variables: age, sex, and the individual smoking reduction
percentage (from baseline CPD to 6-month CPD). Age and sex
had no significant effect (P > 0.05). The effect of reduction
percentage was significant (t = 3.61; P = 0.0006); the greater the
reduction, the more compensation occurred. In addition, wide
variability in compensation scores continued to be observed;
a scatter diagram is shown in Fig. 2. The simple coefficient
of correlation was r = 0.50 (n = 64).
Discussion
The results of this study point to three main conclusions. First,
the extent of tobacco toxicant exposure in former heavy
smokers who significantly reduced their smoking is higher
than those who were consistent light smokers. Given the same
amount of smoking, the amount of total NNAL exposure per
cigarette in reducers was two to three times higher than
existing light smokers. Furthermore, the results showed that
the greater the reduction in smoking, the greater the amount of
compensatory smoking that occurred. That is, smokers who
reduced their smoking to one to three CPD experienced a 4- to
8-fold increased exposure to 4-(methylnitrosamino)-I-(3-pyr-
idyl)-1-butanone per cigarette compared with light smokers.
In general, these findings are concordant with the results
from epidemiologic studies that have compared morbidity
and mortality risk among smokers who have reduced their
smoking by at least 50% with continuous light smokers. For
example, one study found that the amount of risk for lung
cancer among reducers compared with continuous heavy
smokers [HR, 0.73; 95% confidence interval (95% CI), 0.54-0.98]
was f1.7 times that of light smokers (HR, 0.44; 95% CI, 0.35-
0.56), although the mean number of cigarettes was equivalent
if not slightly higher among light smokers (8). Another study
that examined the effects of cigarette reductions of z50% in
decreasing hospitalizations for chronic obstructive pulmonary
disease showed no significant decrease in risk for hospitaliza-
tion among reducers compared with continuous heavy
smokers (HR, 0.93; 95% CI, 0.73-1.18) but a significantly lower
risk in continuous light smokers compared with heavy
smokers (HR, 0.59; 95% CI, 0.51-0.70; ref. 12). For fatal and
nonfatal myocardial infarction, these investigators also found
that reducers did not experience a significant risk reduction
(HR, 1.15; 95% CI, 0.94-1.40) but a modest risk reduction was
observed for light smokers (HR, 0.86; 95% CI, 0.70-0.98; ref. 13).
These differences in risk across disease states between
reducers and light smokers were attributed by these authors
to compensatory smoking. It should be emphasized that, even
Table 2. Average CRRs and their variations in light smokers and reducers
CPD Light smokers (n) Reducers (n) Mean total NNAL (pmol/mg creatinine) Average CRR
Light smokers Reducers (at 6 mo)
1 7 9 0.3256 1.4151 4.35
2 7 11 0.2963 2.4921 8.41
3 8 6 0.4524 2.2360 4.94
4 2 6 1.9449 1.8355 0.94
5 9 4 0.7133 2.2130 3.10
6 2 7 0.9594 1.9220 2.00
7 8 5 1.0064 3.1562 3.14
8 4 2 0.9369 0.9126 0.97
9 3 2 1.3497 3.0076 2.23
10 12 12 1.3918 1.8173 1.31
Figure 2. CRR versus smoking reduction percentage.
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with lower levels of disease risk among continuous light
smokers, a very low rate of smoking still confers increased risk
compared with nonsmokers and quitters (14, 15).
Second, this new method of calculating compensatory
smoking has an advantage over prior methods, which have
relied on using baseline measures of smoke exposure
(i.e., biomarkers per cigarette) as a point of comparison.
Compensatory smoking observed in previous studies may be
influenced by a ‘‘nonlinear relationship’’ between the amount
of tobacco consumption and the level of tobacco toxin
exposure (total NNAL; ref. 16) such that a small reduction in
cigarette smoking by heavy smokers could lead to an increase
in exposure rate. In this study, this confounding effect was
overcome by not using baseline measures of markers but by
using a control group of light smokers who have a comparable
level of cigarette smoking. By ruling out the confounding effect
of the nonlinear relationship between tobacco consumption
and tobacco toxin exposure, we can conclusively attribute the
increased toxicant exposure in reducers compared with light
smokers to smoking compensation.
Third, there is no suggestion that sex has an effect on the
extent of compensatory smoking. These results, on the surface,
seem contradictory to previous studies, which have shown that
women have more difficulty discriminating across different
doses of nicotine compared with men (17), show less nicotine
regulation (18, 19), and are less sensitive to the withdrawal
symptom relief of nicotine (20). However, our findings do not
rule out the hypothesis that compensatory smoking in women
may be more a function of compensating for the sensory
aspects of smoking compared with compensating for reduced
levels of nicotine.
As a caveat, this study did not take into account potential
differences in brand and type of cigarettes smoked (regular,
light, or ultralight) or exposure to secondhand smoke. That is,
it is possible that reducers tended to smoke cigarettes that are
associated with higher tar exposure and/or to be exposed to
greater amounts of secondhand smoke, accounting for the
higher total NNAL in reducers. Using existing data, in a post
hoc analysis, no significant effects were found for types of
cigarettes on relative exposure to total NNAL when matching
for number of cigarettes (P = 0.93) or when looking within the
light smokers or reducers (P = 0.98 and 0.61, respectively).
Furthermore, a previous study has also shown no differences
in levels of toxicant exposure across types of cigarettes (21).
With regards to the issue of secondhand smoke, the contribu-
tion of secondhand smoke to the levels of toxicant exposure
observed from cigarette smoking in reducers compared with
light smokers is likely to be minimal (22).
In summary, the results of this study show that smokers
who reduce cigarette smoking experience greater toxicant
exposure than those who are persistent light smokers even
when matching for number of cigarettes smoked at the time of
assessment. Therefore, simple emphasis on total cigarette
reduction belies the effects of compensation on maintaining
potentially toxic or carcinogenic levels of chemicals in smokers
who reduce their smoking. These results are consistent with
the epidemiologic studies for disease risk, showing higher
risks for reducers than light smokers. To date, the absolute
threshold levels of toxicant exposure that leads to ‘‘significant’’
reduction in tobacco-related illnesses remain unknown and are
likely to vary depending on the physiologic vulnerabilities of
the smoker. Therefore, smoking cessation should continue to
be the message as the end goal for intervention.
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